New This Week
January 16, 2017
- New American Academy of Orthopaedic Surgeons Guidelines on:
- Treatment of Anterior Cruciate Ligament Injuries
- Management of Osteochondritis Dissecans of the Femoral Condyle
- Updated Institute for Clinical Systems Improvement Guidelines on:
- Healthy Lifestyles
- Adult Depression in Primary Care
January 16, 2017
U.S. FDA Advisory
December 16, 2016: Chantix (varenicline) and Zyban (bupropion) : Based on an FDA review of a large clinical trial that FDA required the drug companies to conduct, FDA determined the risk of serious side effects on mood, behavior, or thinking with the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) is lower than previously suspected. The risk of these mental health side effects is still present, especially in those currently being treated for mental illnesses such as depression, anxiety disorders, or schizophrenia, or who have been treated for mental illnesses in the past. However, most people who had these side effects did not have serious consequences such as hospitalization. The results of the trial confirm that the benefits of stopping smoking outweigh the risks of these medicines.
Registration is now open for the Evidence-based Guidelines Affecting Policy, Practice and Stakeholders (E-GAPPS III) Conference. It will be held March 20-21, 2017 at The New York Academy of Medicine.
NGC supports AHRQ's mission to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable by providing objective, detailed information on clinical practice guidelines, and to further their dissemination, implementation, and use in order to inform health care decisions.